Fsd Pharma (TSE:HUGE) has released an update.
FSD Pharma Inc. has announced the submission of a Phase-1b clinical trial application in Australia for its proprietary beverage, unbuzzd™, aimed at enhancing cognition and accelerating alcohol metabolism. The trial, set to recruit healthy volunteers post-approval, will assess the product’s safety and efficacy in individuals experiencing alcohol intoxication. The development of unbuzzd™ is a testament to FSD Pharma’s commitment to science-driven solutions in the biopharmaceutical arena.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
